233 related articles for article (PubMed ID: 25290818)
1. Different effects of fenofibrate on metabolic and cardiovascular risk factors in mixed dyslipidemic women with normal thyroid function and subclinical hypothyroidism.
Krysiak R; Gilowski W; Szkrobka W; Okopien B
Cardiovasc Ther; 2014 Dec; 32(6):264-9. PubMed ID: 25290818
[TBL] [Abstract][Full Text] [Related]
2. The Effect of Testosterone and Fenofibrate, Administered Alone or in Combination, on Cardiometabolic Risk Factors in Men with Late-Onset Hypogonadism and Atherogenic Dyslipidemia.
Krysiak R; Gilowski W; Okopien B
Cardiovasc Ther; 2015 Oct; 33(5):270-4. PubMed ID: 26031507
[TBL] [Abstract][Full Text] [Related]
3. Different effects of fenofibrate on cardiometabolic risk factors in young women with and without hyperprolactinemia.
Krysiak R; Szkróbka W; Okopień B
Pharmacol Rep; 2019 Feb; 71(1):61-66. PubMed ID: 30469130
[TBL] [Abstract][Full Text] [Related]
4. The effect of fenofibrate on cardiometabolic risk factors in bromocriptine-treated women with mixed dyslipidemia: A pilot study.
Krysiak R; Okrzesik J; Szkrobka W; Okopień B
Pharmacol Rep; 2016 Feb; 68(1):185-9. PubMed ID: 26721371
[TBL] [Abstract][Full Text] [Related]
5. Different effects of atorvastatin on metabolic and cardiovascular risk factors in hypercholesterolemic women with normal thyroid function and subclinical hypothyroidism.
Krysiak R; Gilowski W; Okopien B
Exp Clin Endocrinol Diabetes; 2015 Mar; 123(3):182-6. PubMed ID: 25658659
[TBL] [Abstract][Full Text] [Related]
6. The influence of fenofibrate on lipid profile, endothelial dysfunction, and inflammatory markers in type 2 diabetes mellitus patients with typical and mixed dyslipidemia.
Ghani RA; Bin Yaakob I; Wahab NA; Zainudin S; Mustafa N; Sukor N; Wan Mohamud WN; Kadir KA; Kamaruddin NA
J Clin Lipidol; 2013; 7(5):446-53. PubMed ID: 24079286
[TBL] [Abstract][Full Text] [Related]
7. Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance.
Okopień B; Krysiak R; Herman ZS
J Clin Endocrinol Metab; 2006 May; 91(5):1770-8. PubMed ID: 16492702
[TBL] [Abstract][Full Text] [Related]
8. The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia.
Agouridis AP; Tsimihodimos V; Filippatos TD; Dimitriou AA; Tellis CC; Elisaf MS; Mikhailidis DP; Tselepis AD
Expert Opin Pharmacother; 2011 Dec; 12(17):2605-11. PubMed ID: 21714585
[TBL] [Abstract][Full Text] [Related]
9. Metabolic and monocyte-suppressing actions of fenofibrate in patients with mixed dyslipidemia and early glucose metabolism disturbances.
Krysiak R; Stachura-Kułach A; Okopień B
Pharmacol Rep; 2010; 62(1):120-30. PubMed ID: 20360622
[TBL] [Abstract][Full Text] [Related]
10. The effect of soy phytoestrogen supplementation on thyroid status and cardiovascular risk markers in patients with subclinical hypothyroidism: a randomized, double-blind, crossover study.
Sathyapalan T; Manuchehri AM; Thatcher NJ; Rigby AS; Chapman T; Kilpatrick ES; Atkin SL
J Clin Endocrinol Metab; 2011 May; 96(5):1442-9. PubMed ID: 21325465
[TBL] [Abstract][Full Text] [Related]
11. Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (≥ 2 mg/L). cmb@bcm.tmc.edu.
Ballantyne CM; Davidson MH; Setze CM; Kelly MT
J Clin Lipidol; 2011; 5(5):401-7. PubMed ID: 21981842
[TBL] [Abstract][Full Text] [Related]
12. Well-being, health-related quality of life and cardiovascular disease risk profile in women with subclinical thyroid disease - a community-based study.
Bell RJ; Rivera-Woll L; Davison SL; Topliss DJ; Donath S; Davis SR
Clin Endocrinol (Oxf); 2007 Apr; 66(4):548-56. PubMed ID: 17371474
[TBL] [Abstract][Full Text] [Related]
13. Macroprolactinaemia modulates cardiometabolic effects of fenofibrate in men with atherogenic dyslipidaemia: A pilot study.
Krysiak R; Kowalcze K; Okopień B
J Clin Pharm Ther; 2020 Feb; 45(1):115-121. PubMed ID: 31444987
[TBL] [Abstract][Full Text] [Related]
14. The Effect of Atorvastatin on Cardiometabolic Risk Factors in Bromocriptine-Treated Premenopausal Women with Isolated Hypercholesterolemia.
Krysiak R; Gilowski W; Szkrobka W; Okopien B
Cardiovasc Ther; 2015 Oct; 33(5):282-7. PubMed ID: 26146893
[TBL] [Abstract][Full Text] [Related]
15. Subclinical hypothyroidism, lipid metabolism and cardiovascular disease.
Delitala AP; Fanciulli G; Maioli M; Delitala G
Eur J Intern Med; 2017 Mar; 38():17-24. PubMed ID: 28040402
[TBL] [Abstract][Full Text] [Related]
16. Hemostatic effects of fenofibrate in patients with mixed dyslipidemia and impaired fasting glucose.
Krysiak R; Handzlik G; Okopień B
Pharmacol Rep; 2010; 62(6):1099-107. PubMed ID: 21273667
[TBL] [Abstract][Full Text] [Related]
17. Subclinical hypothyroidism and cardiovascular risk.
Vayá A; Giménez C; Sarnago A; Alba A; Rubio O; Hernández-Mijares A; Cámara R
Clin Hemorheol Microcirc; 2014; 58(1):1-7. PubMed ID: 25339098
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the effects of hypolipidemic treatment on monocyte proinflammatory cytokine release in men and women with type 2 diabetes and atherogenic dyslipidemia.
Krysiak R; Gdula-Dymek A; Marek B; Okopień B
Endokrynol Pol; 2015; 66(3):224-30. PubMed ID: 26136131
[TBL] [Abstract][Full Text] [Related]
19. Thyroid dysfunction and their relation to cardiovascular risk factors such as lipid profile, hsCRP, and waist hip ratio in Korea.
Jung CH; Sung KC; Shin HS; Rhee EJ; Lee WY; Kim BS; Kang JH; Kim H; Kim SW; Lee MH; Park JR; Kim SW
Korean J Intern Med; 2003 Sep; 18(3):146-53. PubMed ID: 14619383
[TBL] [Abstract][Full Text] [Related]
20. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Keech A; Simes RJ; Barter P; Best J; Scott R; Taskinen MR; Forder P; Pillai A; Davis T; Glasziou P; Drury P; Kesäniemi YA; Sullivan D; Hunt D; Colman P; d'Emden M; Whiting M; Ehnholm C; Laakso M;
Lancet; 2005 Nov; 366(9500):1849-61. PubMed ID: 16310551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
